News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Pharma Announces the Initiation of the Phase II Clinical Trial With Validive® in the United States


6/10/2013 10:32:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces the initiation of its Phase II clinical trial evaluating the efficacy and safety of ValidiveĀ® (clonidine LauriadĀ®) in the United States in patients with chemoradiation therapy-induced oral mucositis with head and neck cancer, as scheduled in the advancement calendar of the project.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES